![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
R Maldonado, L Stinus, LH Gold and GF Koob
Department of Neuropharmacology, Scripps Research Institute, La Jolla, California.
The aim of this study was to investigate the neuroanatomical regions implicated in the expression of the physical signs of morphine withdrawal by using local intracerebral injections of methylnaloxonium in dependent rats. Guide cannulas were implanted and aimed at the lateral ventricle, nucleus accumbens, central amygdala, anterior hypothalamus, medial thalamus, periaqueductal gray matter, locus coeruleus and nucleus raphe magnus. After surgery, rats were made physically dependent by s.c. implantation of two 75-mg morphine pellets. Methylnaloxonium, a quaternary derivative of naloxone (31-1000 ng), was administered 72 hr after pellet implantation. Methylnaloxonium administered i.c.v. induced a withdrawal syndrome similar to systemic naloxone, although several signs such as diarrhea, salivation, lacrimation and rhinorrhea did not appear, suggesting possible peripheral mediation. The most sensitive site for methylnaloxonium- precipitated withdrawal was the locus coeruleus. Signs such as jumping, rearing and locomotor activity were particularly frequent after methylnaloxonium injections into the locus coeruleus. Rearing and locomotor activity were also strongly increased after methylnaloxonium administration into the periaqueductal gray matter. Wet dog shakes were mainly observed after methylnaloxonium administration into the anterior preoptic hypothalamus and nucleus raphe magnus. Injections of methylnaloxonium into the amygdala produced a weak withdrawal syndrome, and the nucleus accumbens and medial thalamus were the least sensitive structures. These results suggest that the locus coeruleus, and secondarily the periaqueductal gray matter, play an important role in the precipitation of the physical signs of opiate withdrawal, mainly in the expression of its motor component. The expression of other signs of withdrawal appear to be multisite determined.
This article has been cited by other articles:
|
|
 |
|
  A. Kreibich, B. A. S. Reyes, A. L. Curtis, L. Ecke, C. Chavkin, E. J. V. Bockstaele, and R. J. Valentino Presynaptic Inhibition of Diverse Afferents to the Locus Ceruleus by {kappa}-Opiate Receptors: A Novel Mechanism for Regulating the Central Norepinephrine System J. Neurosci., June 18, 2008; 28(25): 6516 - 6525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Domokos, Z. Mergl, I. Barna, G. B Makara, and D. Zelena Congenital vasopressin deficiency and acute and chronic opiate effects on hypothalamo-pituitary adrenal axis activity in Brattleboro rats J. Endocrinol., January 1, 2008; 196(1): 113 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Raehal, J. J. Lowery, C. M. Bhamidipati, R. M. Paolino, J. R. Blair, D. Wang, W. Sadee, and E. J. Bilsky In Vivo Characterization of 6{beta}-Naltrexol, an Opioid Ligand with Less Inverse Agonist Activity Compared with Naltrexone and Naloxone in Opioid-Dependent Mice J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1150 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Holtzman Discrimination of a Single Dose of Morphine Followed by Naltrexone: Substitution of Other Agonists for Morphine and Other Antagonists for Naltrexone in a Rat Model of Acute Dependence J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Sell and C. P. France Cocaine and Amphetamine Attenuate the Discriminative Stimulus Effects of Naltrexone in Opioid-Dependent Rhesus Monkeys J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1103 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Maldonado and F. Rodriguez de Fonseca Cannabinoid Addiction: Behavioral Models and Neural Correlates J. Neurosci., May 1, 2002; 22(9): 3326 - 3331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Z. Shaw-Lutchman, M. Barrot, T. Wallace, L. Gilden, V. Zachariou, S. Impey, R. S. Duman, D. Storm, and E. J. Nestler Regional and Cellular Mapping of cAMP Response Element-Mediated Transcription during Naltrexone-Precipitated Morphine Withdrawal J. Neurosci., May 1, 2002; 22(9): 3663 - 3672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Schad, J. B. Justice Jr., and S. G. Holtzman Endogenous Opioids in Dopaminergic Cell Body Regions Modulate Amphetamine-Induced Increases in Extracellular Dopamine Levels in the Terminal Regions J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 932 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Nieto, J. Wilson, A. Cupo, B. P. Roques, and F. Noble Chronic Morphine Treatment Modulates the Extracellular Levels of Endogenous Enkephalins in Rat Brain Structures Involved in Opiate Dependence: A Microdialysis Study J. Neurosci., February 1, 2002; 22(3): 1034 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Williams, M. J. Christie, and O. Manzoni Cellular and Synaptic Adaptations Mediating Opioid Dependence Physiol Rev, January 1, 2001; 81(1): 299 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Laorden, G. Fuertes, A. González-Cuello, and M. V. Milanés Changes in Catecholaminergic Pathways Innervating Paraventricular Nucleus and Pituitary-Adrenal Axis Response during Morphine Dependence: Implication of alpha 1- and alpha 2-Adrenoceptors J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 578 - 584. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. D. Pomonis, D. C. Jewett, C. M. Kotz, J. E. Briggs, C. J. Billington, and A. S. Levine Sucrose consumption increases naloxone-induced c-Fos immunoreactivity in limbic forebrain Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2000; 278(3): R712 - R719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Caillé, E. F. Espejo, J.-P. Reneric, M. Cador, G. F. Koob, and L. Stinus Total Neurochemical Lesion of Noradrenergic Neurons of the Locus Ceruleus Does Not Alter Either Naloxone-Precipitated or Spontaneous Opiate Withdrawal nor Does It Influence Ability of Clonidine To Reverse Opiate Withdrawal J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 881 - 892. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Wang, R. K. Freund, and M. R. Palmer Potentiation of Ethanol Effects in Cerebellum by Activation of Endogenous Noradrenergic Inputs J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 211 - 220. [Abstract] [Full Text]
|
|
|
|
|
|
S. L. Ingram, C. W. Vaughan, E. E. Bagley, M. Connor, and M. J. Christie Enhanced Opioid Efficacy in Opioid Dependence Is Caused by an Altered Signal Transduction Pathway J. Neurosci., December 15, 1998; 18(24): 10269 - 10276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chieng and J. T. Williams Increased Opioid Inhibition of GABA Release in Nucleus Accumbens during Morphine Withdrawal J. Neurosci., September 1, 1998; 18(17): 7033 - 7039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.V. Milanés, M.L. Laorden, M. Chapleur-Château, and A. Burlet Alterations in Corticotropin-Releasing Factor and Vasopressin Content in Rat Brain during Morphine Withdrawal: Correlation with Hypothalamic Noradrenergic Activity and Pituitary-Adrenal Response J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 700 - 706. [Abstract] [Full Text]
|
|
|
|
|
|
D. P. D. Woldbye, K. Klemp, and T. M. Madsen Neuropeptide Y Attenuates Naloxone-Precipitated Morphine Withdrawal via Y5-like Receptors J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 633 - 636. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. R. Walker and G. F. Koob Orphan anxiety PNAS, December 23, 1997; 94(26): 14217 - 14219. [Full Text] [PDF]
|
|
|
|
|
|
L. J. Punch, D. W. Self, E. J. Nestler, and J. R. Taylor Opposite Modulation of Opiate Withdrawal Behaviors on Microinfusion of a Protein Kinase A Inhibitor Versus Activator into the Locus Coeruleus or Periaqueductal Gray J. Neurosci., November 1, 1997; 17(21): 8520 - 8527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yu, E. R. Butelman, J. H. Woods, B. T. Chait, and M. J. Kreek Dynorphin A (1-8) Analog, E-2078, Crosses the Blood-Brain Barrier in Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 633 - 638. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Hepburn, P. J. Little, J. Gingras, and C. M. Kuhn J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1350 - 1356. [Abstract] [Full Text]
|
|
|
|
|
|
K. W. Easterling and S. G. Holtzman Intracranial Self-Stimulation in Rats: Sensitization to an Opioid Antagonist Following Acute or Chronic Treatment with Mu Opioid Agonists, J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 188 - 199. [Abstract] [Full Text]
|
|
|
|
|
|
B. Chieng and M. J. Christie Local Opioid Withdrawal in Rat Single Periaqueductal Gray Neurons In Vitro J. Neurosci., November 15, 1996; 16(22): 7128 - 7136. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
